Compare Chipotle Mexican Grill, Inc. (CMG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Pfizer Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.15 (market cap $40.67B), while Pfizer Inc trades at $26.53 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 3.8× Chipotle Mexican Grill, Inc.'s market cap, and Pfizer Inc pays a 6.36% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| CMG | PFE | |
|---|---|---|
Market Cap | $40.67B | $154.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $28.56 |
52-Week Low | $28.17 | $23.60 |
Enterprise Value | $45.42B | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.81, down 2.67% amid food safety concerns. The stock shows bearish technical signals with strong analyst support (70% buy ratings) and a $42.17 consensus target. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.33 exceeding estimates. Revenue growth remains steady, climbing from $8.6B in 2022 to $11.9B in 2025, though net income margin compressed to 11.42% in 2026 from 13.55% in 2024.
Despite strong fundamentals and analyst optimism, CMG faces near-term headwinds from salmonella outbreaks and fraud investigations. The stock's premium valuation (P/E 29.76) requires sustained execution amid operational challenges. Long-term growth trajectory remains intact, but current sentiment is cautious due to food safety issues and legal scrutiny.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
